This site is intended for US Healthcare Professionals

Inflammation from Demodex may cause serious consequences, like DB and MGD1-3

Patients with both may experience3,4:

Fluctuating vision

Itching

Redness

Within the meibomian gland, mites may cause1,2,5:

  • Inflammation and obstruction of the gland orifices
  • Reduced gland expressibility
  • Gland atrophy or loss
  • Decrease in meibum quality

That’s where
XDEMVY comes in

ERSA and RHEA were 2 separate, randomized pilot studies evaluating the safety and efficacy of XDEMVY and vehicle for the treatment of DB patients with MGD. Eligibility criteria and endpoints for the ERSA and RHEA studies were identical.6

ERSA and RHEA studies6

There were no treatment-related serious adverse events6

Get the info you need to send Demodex mites packing

Sign Up for Updates

References: 1. Zhang XB, Ding YH, He W. The association between Demodex infestation and ocular surface manifestations in meibomian gland dysfunction. Int J Ophthalmol. 2018;11(4):589-592. 2. Liu J, Sheha H, Tseng SCG. Pathogenic role of Demodex mites in blepharitis. Curr Opin Allergy Clin Immunol. 2010;10(5):505-510. 3. Fromstein SR, Harthan JS, Patel J, Opitz DL. Demodex blepharitis: clinical perspectives. Clin Optom (Auckl). 2018;10:57-63. 4. Meibomian gland dysfunction and treatment. American Association for Pediatric Ophthalmology & Strabismus. Updated March 2023. Accessed December 4, 2024. https://aapos.org/glossary/meibomian-gland-dysfunction-and-treatment 5. Lee WJ, Kim M, Lee SH, Chun YS, Kim KW. The varied influence of ocular Demodex infestation on dry eye disease and meibomian gland dysfunction across different age groups. Sci Rep. 2023;13(1):16324. 6. Data on file, Tarsus Pharmaceuticals, Inc.


INDICATIONS AND USAGE
XDEMVY (lotilaner ophthalmic solution) 0.25% is indicated for the treatment of Demodex blepharitis.

IMPORTANT SAFETY INFORMATION:

WARNINGS AND PRECAUTIONS

Risk of Contamination: Do not allow the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

Use with Contact Lenses: XDEMVY contains potassium sorbate, which may discolor soft contact lenses. Contact lenses should be removed prior to instillation of XDEMVY and may be reinserted 15 minutes following its administration.

ADVERSE REACTIONS: The most common adverse reaction with XDEMVY was instillation site stinging and burning which was reported in 10% of patients. Other ocular adverse reactions reported in less than 2% of patients were chalazion/hordeolum and punctate keratitis.

To report SUSPECTED ADVERSE REACTIONS, contact Tarsus Pharmaceuticals, Inc. at 1-888-421-4002 or the FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Please see full Prescribing Information.

INDICATIONS AND USAGE
XDEMVY (lotilaner ophthalmic solution) 0.25% is indicated for the treatment of Demodex blepharitis.

IMPORTANT SAFETY INFORMATION:

WARNINGS AND PRECAUTIONS

Risk of Contamination: Do not allow the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.